BACE Inhibitors Clinical Trials & Results, Collaboration, and Developments

The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.

As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis

Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample

Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.

Designed by CyFocus.com
Powered by CyFocus.net